by IgNS | Mar 14, 2020 | Latest News
COVID-19 Update IgNS thanks all healthcare professionals and service providers, first responders, government agencies, and the healthcare industry who are working tirelessly in the face of the COVID-19 pandemic. Roche receives emergency approval for COVID-19...
by IgNS | Feb 27, 2020 | Latest News
Novel Coronavirus (COVID-19 or SARS-CoV-2) and Plasma Safety IgNS Statement Regarding the Novel Coronavirus (COVID-19 or SARS-CoV-2) The recent outbreak of the 2019 Novel Coronavirus (COVID-19 or SARS-CoV-2) has raised awareness around the safety of plasma...
by IgNS | Sep 24, 2019 | Latest News
On Sept. 23, the Healthcare Quality and Safety team at USP issued a letter announcing that it would delay the planned Dec. 1 implementation of three of its chapters: the revised <795> Pharmaceutical Compounding—Nonsterile Preparations and <797>...
by IgNS | Jul 17, 2019 | Latest News
Examining the Application of Immunoglobulin in Multiple Disease States: A Review of Evidence Activity Overview: The administration of immunoglobulin (Ig) has become common practice in the treatment of patients with immunodeficiencies, and, more recently, in other...
by IgNS | Nov 6, 2018 | Latest News
Immunoglobulin National Society (IgNS) is pleased to announce a two-year corporate sponsorship agreement with Managed Health Care Associates, Inc., a health care services and software company based in Florham Park, NJ. This sponsorship agreement is part of both...
by IGNS | Oct 24, 2017 | Latest News
LOS ANGELES, CA (PRWEB) OCTOBER 24, 2017 Immunoglobulin National Society (IgNS) announced Stacey Ness, Pharm.D, RPh, CSP, MSCS, AAHIVP will become the next President, serving a two-year term effective January 1, 2018. Dr. Ness brings a wealth of clinical expertise in...
